MGMT promoter methylation in plasma of glioma patients receiving temozolomide

By Fiano Valentina   Trevisan Morena   Trevisan Elisa   Senetta Rebecca   Castiglione Anna   Sacerdote Carlotta   Gillio-Tos Anna   Marco Laura   Grasso Chiara   Magistrello Michela   Tondat Fabrizio   Rudà Roberta   Cassoni Paola   Soffietti Riccardo   Merletti Franco  

Journal of Neuro-Oncology, Vol. 117, Iss. 2, 2014-04 ,pp. : 347-357

Springer Publishing Company

Access to resources Recommend Favorite

MGMT promoter methylation in malignant gliomas

By Riemenschneider Markus  

Targeted Oncology, Vol. 5, Iss. 3, 2010-09 ,pp. : 161-165

Springer Publishing Company

Access to resources Recommend Favorite

Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07

By                      

Oncology Reports, Vol. 28, Iss. 2, 2012-01 ,pp. : 654-658

Spandidos Publications

Access to resources Recommend Favorite

MGMT promoter methylation status in anaplastic meningiomas

By Brokinkel Benjamin   Fischer Bernhard   Peetz-Dienhart Susanne   Ebel Heinrich   Sepehrnia Abolghassem   Rama Burckhard   Albert Friedrich   Stummer Walter   Paulus Werner   Hasselblatt Martin  

Journal of Neuro-Oncology, Vol. 100, Iss. 3, 2010-12 ,pp. : 489-490

Springer Publishing Company

Access to resources Recommend Favorite

Promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinoma

By Banzai Chiaki   Nishino Koji   Quan Jinhua   Yoshihara Kosuke   Sekine Masayuki   Yahata Tetsuro   Tanaka Kenichi  

International Journal of Clinical Oncology, Vol. 19, Iss. 1, 2014-02 ,pp. : 127-132

Springer Publishing Company

Access to resources Recommend Favorite